Clarity Pharmaceuticals Ltd News

S&P DJI Announces December 2024 Quarterly Rebalance

Dec 6 14:08

Clarity Pharmaceuticals Ltd: Last patient assessment completed for SARTATE trial

Nov 28 06:57

Clarity Pharmaceuticals Ltd: First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA

Nov 26 06:56

Clarity Pharmaceuticals Ltd: Chairperson Address AGM

Nov 20 06:27

Clarity Pharmaceuticals Ltd: Head-to-head IIT with SAR-bisPSMA

Nov 18 06:36

Clarity Pharmaceuticals Ltd: Clarity and Nucleus RadioPharma sign MSA

Nov 11 06:37

Clarity Pharmaceuticals Ltd: CMS final rule on radio-diagnostic reimbursement policy

Nov 5 06:50

Clarity Pharmaceuticals Ltd: Notice of Annual General Meeting/Proxy Form

Oct 18 07:50

Clarity Pharmaceuticals Ltd: Copper-67 SAR-bisPSMA updates

Oct 16 06:33

Clarity Pharmaceuticals Ltd: Positive guidance from the US FDA on Phase III trial

Oct 14 06:49

Clarity Pharmaceuticals Ltd: Michelle Parker Promoted to CEO

Oct 14 06:45

Clarity Pharmaceuticals Ltd: Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA

Oct 8 06:52

Clarity Pharmaceuticals Ltd: COBRA study selected as a Top-Rated Oral Presentation

Oct 1 07:51

Clarity Pharmaceuticals Ltd: CORPORATE GOVERNANCE STATEMENT

Sep 30 13:11

Clarity Pharmaceuticals Ltd: Appendix 4G

Sep 30 13:10

Clarity Pharmaceuticals Ltd: Date of Annual General Meeting

Sep 23 14:30

Clarity Pharmaceuticals Ltd: Initial Director's Interest Notice - Parker

Sep 20 12:48

Clarity Pharmaceuticals Ltd: Change of Director's Interest Notice - Robinson

Sep 18 14:04

Clarity Pharmaceuticals Ltd: SECuRE trial advances

Sep 12 07:14

Clarity Pharmaceuticals Ltd: Final Director's Interest Notice - Rob Thomas

Aug 26 10:20